The company expects to launch more than 20 pivotal late-stage trials this year.

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer posted adjusted earnings of 66 cents per share, beating the 57 cents forecast by analysts, News.Az reports, citing foreign ...

Pfizer highlighted another fall in quarterly revenues tied to Covid-19 products, and $4.4 billion in asset impairments ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets ...

The patent cliff looms large. UBS analyst Michael Yee pointed to roughly "$15-20B in revenues from key drugs losing patent exclusivity" over the next three years, including blockbusters Vyndaquel, ...